non-reliance periods, the estimated impact of adjustments to the financial statements for the applicable
non-reliance periods, the impact of the Company’s material weakness in internal control over financial reporting and the Company’s disclosure controls and procedures on its financial statements and
other public disclosures, the anticipated timing for filing the Company’s restated reports and the Form 10-Q for the third quarter of 2023 and related matters. These statements are often
identified by the use of words such as “anticipate,” “believe,” “contemplate,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,”
“outlook,” “plan,” “predict,” “project,” “see,” “seek,” “target,” “would” and similar expressions or variations or negatives of these words, although not all
forward-looking statements contain these identifying words. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions
of actual performance. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risk and
uncertainties related to: (i) our failure to promptly restate the financial statements for the applicable non-reliance periods and file the required reports with the Securities and Exchange Commission
(the “SEC”) and (ii) the impact of the restatements of the financial statements on the price of our common stock, our reputation, our relationships with our investors, suppliers, customers, employees and other parties. Additional
risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2022 and any other periodic reports that the Company may file with the SEC. Subsequent events and developments, including actual results or changes in the Company’s
assumptions, may cause the Company’s views to change. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. You are cautioned not to place undue reliance on such
forward-looking statements.
Non-GAAP Financial Measures
In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the
Company supplements its GAAP consolidated financial statements with certain non-GAAP financial measures, including adjusted EBITDA. Adjusted EBITDA is defined as GAAP net income (loss) before net interest
income/expense, income tax provision/benefit, depreciation and amortization expense, share-based compensation expense, CoyCo 2, L.P. share-based compensation expense, and certain other items, including business acquisition costs, integration costs,
technology transformation, strategic initiatives, the global business services center expansion project in the Philippines and facility-exit charges.
Our
board of directors and management team use adjusted EBITDA as (i) one of the primary methods for planning and forecasting overall expectations and for evaluating actual results against such expectations and (ii) a performance evaluation
metric in determining achievement of certain executive incentive compensation programs, as well as for incentive compensation programs for employees.
Table 1 presents a reconciliation of Adjusted EBITDA guidance to GAAP operating income guidance. Non-GAAP measures
should be considered in addition to, but not as a substitute for, the information prepared in accordance with GAAP.
About R1 RCM
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. R1’s
proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient
experience. To learn more, visit: r1rcm.com.